A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs ADH 1 (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Gallbladder cancer; Pancreatic cancer
- Focus Adverse reactions; Biomarker
- 26 Jan 2018 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 08 May 2013 Adherex Technologies added a trial company and lead trial centre as reported by ClinicalTrials.gov.